Welcome to our dedicated page for Lantern Pharma news (Ticker: LTRN), a resource for investors and traders seeking the latest updates and insights on Lantern Pharma stock.
Lantern Pharma Inc. (NASDAQ: LTRN) generates a steady flow of news as an AI-driven, clinical-stage oncology company advancing both a precision medicine pipeline and a proprietary artificial intelligence platform. News coverage on this page centers on developments in its RADR® AI and machine learning platform, clinical trial milestones for LP-184, LP-284, and LP-300, regulatory interactions, and strategic initiatives that shape the company’s position in AI-enabled cancer drug development.
Investors and researchers following LTRN news will find detailed updates on Phase 1 and Phase 2 clinical trials, including safety and efficacy readouts, biomarker findings, and disease control observations in heavily pre-treated cancer patients. Recent announcements have highlighted LP-184’s Phase 1a results in advanced solid tumors, LP-284’s activity in relapsed or refractory B-cell lymphomas, and LP-300 data from the HARMONIC™ trial in never-smoker non-small cell lung cancer. Lantern also reports on FDA designations such as Fast Track, Orphan Drug, and Rare Pediatric Disease status that influence development pathways for its drug candidates.
In addition to clinical results, Lantern’s news stream covers the evolution of its RADR® platform and related AI modules. Articles describe the launch and performance of tools like predictBBB.ai for blood–brain barrier prediction and LBx-AI for liquid biopsy-based treatment response modeling, as well as presentations at scientific meetings and symposia. Corporate news items include quarterly financial updates, at-the-market financing agreements, board appointments, proxy statements, and the announcement of an AI Center of Excellence in Bengaluru, India to scale RADR® and multi-agent AI systems for global biopharma partners.
By reviewing the LTRN news feed, readers can track how Lantern integrates AI, genomics, and clinical data into its oncology programs, how regulators and collaborators engage with its pipeline, and how the company positions its AI modules and partnerships in the broader biopharmaceutical landscape. This page is a resource for monitoring material events, clinical inflection points, and platform advances that Lantern discloses through press releases and regulatory communications.
Lantern Pharma (LTRN) announced promising preclinical data regarding its drug candidate, LP-184, in collaboration with the Fox Chase Cancer Center. The data showed over 90% tumor shrinkage in pancreatic cancer mouse models within 8 weeks, contrasting with significant tumor growth in untreated mice. The study also indicated that LP-184 is effective against various pancreatic cancer cell lines and patient-derived xenograft models, suggesting its potential for targeted therapy. Additionally, the research validated the role of PTGR1 in enhancing the drug's efficacy, supporting future trials aimed at genetically defined patient populations.
Lantern Pharma Inc. (LTRN) reported its financial results for Q1 2021, highlighting significant advancements in its oncology drug pipeline. The company expanded its RADR® A.I. platform to over 4.6 billion datapoints, nearly a 16-fold increase since its IPO. Lantern's collaboration with Actuate Therapeutics aims to improve insights into the 9-ING-41 drug candidate using RADR® technology. As of March 31, 2021, cash and cash equivalents rose to $81.4 million, while the net loss increased to $2.45 million, consistent with the previous year. The company remains focused on advancing clinical trials and potential partnerships.
Lantern Pharma (NASDAQ: LTRN) announced a research and development collaboration with Actuate Therapeutics to utilize its RADR® AI platform in the advancement of Actuate's 9-ING-41 drug candidate, a GSK-3β inhibitor undergoing multiple Phase 2 trials. The collaboration aims to enhance drug development through machine learning and oncology datasets, potentially generating joint intellectual property. Lantern expects its RADR® platform to surpass 10 billion oncology data points within a year, enhancing its capabilities in patient stratification and drug discovery.
Lantern Pharma (LTRN) announced that its RADR® AI platform has surpassed 4.6 billion datapoints, marking a 16-fold increase over the past year. This advancement enhances the platform's drug discovery capabilities across various cancers, focusing on personalized oncology therapeutics. CEO Panna Sharma highlighted the importance of this milestone in speeding up drug development and increasing collaboration opportunities in the biopharma sector. Additionally, Lantern filed two new patents to protect its innovations in AI-driven drug development.
Lantern Pharma (NASDAQ: LTRN), a clinical-stage biopharmaceutical company, will host a conference call on May 3, 2021, at 4:30 p.m. ET to discuss its first-quarter financial and operating results for the period ending March 31, 2021. The call will feature CEO Panna Sharma and other management members. Lantern Pharma utilizes its proprietary RADR® A.I. platform to advance oncology therapeutics and identify responsive patients. More details on the call can be accessed via the company’s website.
Lantern Pharma Inc. (NASDAQ: LTRN) announced the publication of a manuscript in Oncotarget detailing the efficacy of its drug candidate, LP-184, for treating non-small cell lung cancer (NSCLC). LP-184 has shown nanomolar potency against therapy-resistant NSCLC models, surpassing conventional chemotherapeutics in effectiveness. The unmet need addresses patients resistant to current therapies, with 30-40% of lung cancers lacking targetable mutations. The research identifies patient subgroups likely to respond to LP-184, supporting its potential as a viable treatment option in oncology.
Lantern Pharma (NASDAQ: LTRN), a clinical-stage biopharmaceutical company, announced its participation in the virtual 20th Annual Needham Healthcare Conference from April 12-15, 2021. CEO Panna Sharma will engage in a fireside chat on April 15 at 12:45 pm ET and conduct one-on-one investor meetings during the event. The session will be livestreamed and accessible for 90 days on their investor relations website. Lantern Pharma is advancing its proprietary RADR® A.I. platform for oncology drug development, focusing on genomic-targeted therapeutics.
Lantern Pharma (NASDAQ: LTRN), a clinical-stage biopharmaceutical firm, announced a collaboration with Johns Hopkins Pediatric Oncology for its drug candidate LP-184, targeting Atypical Teratoid Rhabdoid Tumors (ATRT) in children, an aggressive brain cancer with no effective treatments. The partnership aims to explore LP-184's efficacy across multiple central nervous system cancers, leveraging Lantern's RADR® AI platform. The FDA's Rare Pediatric Disease Designation may enhance LP-184's development, potentially qualifying for a Priority Review Voucher, adding significant value for Lantern's future prospects.
Lantern Pharma (NASDAQ: LTRN) announced it will present new findings on LP-184, a targeted small molecule for prostate cancer, at the AACR Virtual Annual Meeting from April 10-15, 2021. The data highlights LP-184's effectiveness against DNA damage repair defects found in 25-30% of metastatic prostate cancer patients. CEO Panna Sharma noted the potential for LP-184 to exhibit best-in-class efficacy, particularly in tumors with specific genetic mutations. The findings will be showcased in a poster presentation during the conference.
Lantern Pharma (NASDAQ: LTRN) announced the filing of seven global patent applications for a new DNA-damaging agent, LP-284, with demonstrated anticancer properties. LP-284, a preclinical small molecule candidate, shows promise in various cancer indications by inhibiting DNA damage and repair mechanisms. The distinct characteristics of LP-284, as a stereoisomer of LP-184, may enhance its therapeutic potential and integration into Lantern's portfolio. This strategic move reflects Lantern's ongoing commitment to advancing targeted oncology therapies through its RADR® A.I. platform.